

1 **Single-cell RNA sequencing reveals a novel cell type and immunotherapeutic**  
2 **targets in papillary thyroid cancer**

3 Zhengshi Wang<sup>1,2,†</sup>, Youlutuziayi Rixiati<sup>3,†</sup>, Wenli Jiang<sup>4,†</sup>, Chen Ye<sup>5</sup>, Caiguo Huang<sup>4</sup>,  
4 Chuangang Tang<sup>6,\*</sup>, Zhiqiang Yin<sup>1,2,\*</sup>, Binghua Jiao<sup>4,\*</sup>

5

6 <sup>1</sup> Thyroid Center, Shanghai Tenth People's Hospital, Tongji University School of  
7 Medicine, Shanghai, P.R.China;

8 <sup>2</sup> Shanghai Center for Thyroid Diseases, Shanghai, 200072, P.R.China;

9 <sup>3</sup> Department of Pathology, Soochow University Medical School, Suzhou, 215123,  
10 P.R.China;

11 <sup>4</sup> Department of Biochemistry and Molecular Biology, College of Basic Medical,  
12 Navy Medical University, Shanghai, 200433, P.R.China;

13 <sup>5</sup> Department of Urology, Changhai Hospital, Navy Medical University, Shanghai,  
14 200433, P.R.China;

15 <sup>6</sup> Department of Thyroid and Breast Surgery, Xuzhou Central Hospital, The Affiliated  
16 Xuzhou Hospital of Medical College of Southeast University, Xuzhou, 221009,  
17 P.R.China.

18

19 <sup>†</sup>They contributed equally to the manuscript.

20 **\*Corresponding authors:**

21 **Binghua Jiao**, PhD. Department of Biochemistry and Molecular Biology, College of  
22 Basic Medical, Navy Medical University, Shanghai, 200433, P.R.China. Tel:  
23 +86-13801924888, Email: [biojiao@163.com](mailto:biojiao@163.com).

24 **Zhiqiang Yin**, MD. Shanghai Center for Thyroid Diseases, No. 301, Middle  
25 Yanchang Road, Shanghai, P.R.China. Tel.: +86-18917689323, Email:  
26 [972683004@qq.com](mailto:972683004@qq.com)

27 **Chuangang Tang**, MD. Department of Thyroid and Breast Surgery, Xuzhou Central  
28 Hospital, The Affiliated Xuzhou Hospital of Medical College of Southeast University,  
29 Xuzhou, 221009, P.R.China. Tel.: +86-18652230137, Email: [tcg3711@163.com](mailto:tcg3711@163.com).

30 **Abstract**

31 Papillary thyroid cancer (PTC) is the most common thyroid malignancy. Although  
32 PTC usually has a favorable prognosis, some aggressive PTC subtypes and lymph  
33 node (LN) metastasis contribute to high rates of recurrence and poor clinical  
34 outcomes. We analyzed single-cell RNA sequencing (scRNA-seq) data from 15  
35 samples, including primary tumors of PTC, metastatic LNs, and paracancerous tissues.  
36 After quality filtering, 28,205 cells were detected. Of these, 13,390 cells originated  
37 from 7 tumor tissues, 2,869 cells from 2 metastatic LNs, and 11,945 cells from 6  
38 paracancerous tissues. The increase in the proportion of CD4<sup>+</sup> Tregs may be a key  
39 factor responsible for the immunosuppressive property of PTC. A novel cell type was  
40 identified, named Protective EGR1<sup>+</sup>CD4<sup>+</sup> T cell, which might be antagonistic to the  
41 CD4<sup>+</sup> Tregs and inhibit the formation of the immunosuppressive microenvironment  
42 and tumor immune evasion. Inhibitory checkpoints TIGIT and CD96 were found to be  
43 better targets than PD-1 for immune therapy in PTC patients with LN metastasis. For  
44 PTC patients without LN metastasis, however, PD-1, TIGIT, and CD96 could be  
45 suitable targets of immunotherapy. These findings would contribute to the further  
46 understanding of molecular mechanisms resulting in occurrence and development of  
47 PTC, and provide a theoretical rationale for targeted therapy and immunotherapy.

48 **Keywords**

49 papillary thyroid cancer, single-cell RNA sequencing, tumor microenvironment

50

51

## 52 **Introduction**

53 According to the GLOBOCAN database, there were an estimated 586,202 new cases  
54 of thyroid cancer worldwide in 2020 <sup>1</sup>. The global incidence was up to 13.1 per  
55 100,000 people, ranking 11th in occurrence rate. The most common pathological type  
56 of thyroid cancer is papillary thyroid cancer (PTC), accounting for approximately 85%  
57 of all cases <sup>2</sup>. Although PTC usually has a favorable prognosis, some aggressive PTC  
58 subtypes (e.g. tall cell variant and Hürthle cell cancer) and lymph node (LN)  
59 metastasis contribute to high rates of recurrence and poor clinical outcomes <sup>3,4</sup>. For  
60 PTC patients with a high risk of recurrence, radioiodine treatment could be used to  
61 improve their prognosis <sup>5</sup>. However, some PTC patients would develop into  
62 radioiodine-refractory PTC, which in turn lead to low survival rate <sup>6,7</sup>. Therefore, a  
63 deeper understanding of molecular and cellular mechanisms of PTC would help in the  
64 development of therapeutic strategies.

65 Currently, efforts to study the tumor progression and metastatic process of  
66 thyroid cancer have mainly focused on the analysis of cancer cells using genetic  
67 aberrations<sup>8,9,10,11</sup>. However, the tumor progression and metastasis are a complicated  
68 biological process, which were not only affected by the characteristic features of  
69 cancer cells themselves but also by the tumor microenvironment (TME) <sup>12, 13, 14, 15</sup>.  
70 TME refers to a tumor pathology-related environment, comprising stromal cells,  
71 extracellular matrix (ECM), and cytokines. A comprehensive analysis of TME in PTC  
72 can reveal the key elements involved in the susceptibility of tumor-induced  
73 immunological changes, which could be employed to develop new immunotherapy  
74 strategies.

75 Genomic and transcriptomic studies have revealed a huge number of driver  
76 mutations, abnormal regulatory programs, and disease subtypes in major human  
77 tumors<sup>16, 17, 18, 19</sup>. However, the conventional bulk sequencing frequently adopted in  
78 these studies only revealed the overall biological characteristics of each tumor and  
79 lacked the ability to capture signatures in intratumoral and intercellular  
80 heterogeneity. As opposed to bulk sequencing, the emergence of single-cell RNA  
81 sequencing (scRNA-seq) provided a new opportunity to enables characterization of  
82 cell populations at the single-cell level, and made it more independent of any previous  
83 assumptions about surface markers <sup>20</sup>. scRNA-seq has been applied to investigate  
84 cellular properties in various solid tumor types <sup>21</sup>. However, the single-cell atlas of

85 PTC remains to be fully revealed. Therefore, we analyzed primary PTC tumors,  
86 paracancerous tissues, and metastatic LNs using the scRNA-seq-based profiling  
87 method to better understand the intratumoral heterogeneity and complexity during the  
88 development of PTC.

## 89 **Results**

### 90 **Single cell atlas and heterogeneity of PTC**

91 A total of 15 samples from seven PTC patients were involved in this study. After  
92 quality filtering, 28,205 cells were detected. Of these, 13,390 cells originated from 7  
93 tumor tissues, 2,869 cells from 2 metastatic LNs, and 11,945 cells from 6  
94 paracancerous tissues (Fig. 1a and 1b). Subsequently, we partitioned the cells into 26  
95 clusters, which were further classified into 10 major cell types based on known  
96 markers described in previous studies: B cells (CD19<sup>+</sup>, MS4A1<sup>+</sup>, CD38<sup>+</sup>, CD79A<sup>+</sup>,  
97 CD79B<sup>+</sup>); CD4<sup>+</sup> T cells (CD3D<sup>+</sup>, CD4<sup>+</sup>); CD8<sup>+</sup> T cells (CD3D<sup>+</sup>, CD8A<sup>+</sup>); endothelial  
98 cells (CD31<sup>+</sup>, CD34<sup>+</sup>); epithelial cells (EPCAM<sup>+</sup>, KRT18<sup>+</sup>); fibroblasts (COL1A1<sup>+</sup>);  
99 myeloid cells (CD14<sup>+</sup>, CD86<sup>+</sup>, ITGAX<sup>+</sup>, CD80<sup>+</sup>, CD83<sup>+</sup>, ITGAM<sup>+</sup>); naive T cells  
100 (CD3D<sup>+</sup>, CCR7<sup>+</sup>); natural killer T (NKT) cells (CD3D<sup>+</sup>, NKG7<sup>+</sup>); and plasma cells  
101 (CD79A<sup>+</sup>, SDC1<sup>+</sup>) (Fig. 1c, Supplementary Fig. 1 and 2).

102 Based on the frequencies of cell types, we detected cellular landscapes in  
103 primary tumors, paracancerous tissues, and metastatic LNs, respectively. Significant  
104 differences were observed in several cell types (Fig. 1d). The immune cells accounted  
105 for the major differences between primary tumors and paracancerous tissues, with the  
106 frequency of NKT cells and plasma cells increasing, and CD4<sup>+</sup> T cells and B cells  
107 decreasing in the primary tumors ( $P < 0.05$ ). The most striking changes between  
108 metastatic LNs and primary tumors were observed in CD8<sup>+</sup> T cells. At the cluster  
109 level, there were also significant differences within the same cell types. As  
110 exemplified by myeloid cells, we observed an increase in the frequency of cluster 21  
111 and a decrease in the proportion of cluster 25 in metastatic LNs compared with  
112 primary tumors and paracancerous tissues. These results demonstrated that the disease  
113 progression might also be somehow associated with evolutionary immune cells,  
114 reflecting the existence of heterogeneity among samples and cell populations.

115 To conduct the interaction network of tumor microenvironment in PTC,  
116 CellphoneDB was used to calculate potential ligand-receptor pairs in cells. And  
117 Cytoscape was performed to visualize the cell interaction. We found that myeloid  
118 cells and T cell-related cells possessed more interaction pairs with other cells than

119 others (Fig. 1e), showing the dominant roles of myeloid cells and T cells.

#### 120 **Identification of malignant cells in epithelial cells**

121 To distinguish malignant from non-malignant cells within the epithelial cells,  
122 CopyKAT was performed to identify PTC genome alterations. Despite the  
123 heterogeneity, almost all malignant cells possessed deletions from chromosomes 16  
124 and 19 and amplifications in chromosomes 13 (Fig. 2a and 2b). We distinguished  
125 1,679 non-malignant cells and 450 cells were identified as malignant cells. Very few  
126 malignant cells were also found in paracancerous tissues (Fig. 2b). In order to support  
127 the identification results of the malignant cells, pseudotime trajectory analysis was  
128 performed. The results showed that malignant cells were present at the end of the  
129 differentiation trajectory (Fig. 2c).

130 To screen for key regulons in malignant cells, we conducted SCENIC analysis  
131 and identified motifs ATF3 and BHLHE40 that were highly activated in malignant  
132 cells (Fig. 2d). In a previous study, ATF3 was found to enhance breast cancer  
133 metastasis<sup>36</sup>. At the same time, decreased activity was found in CREM and ETS1. In  
134 TCGA THCA cohort, a high level of CREM and ETS1 was significantly related to a  
135 good prognosis, and BHLHE40 is highly expressed in patients with LN metastasis  
136 compared with patients without LN metastasis (Fig. 2e and 2f). These results provide  
137 potential targets for suppressing cells to possess malignant characteristics.

138 We further characterized the functions of differential genes between metastatic  
139 LNs and primary tumors by comparing pathway activities. Pathways involved in  
140 cellular component assembly, protein-containing complex assembly, and regulation of  
141 microtubule motor activity were relatively upregulated in LN-derived malignant cells  
142 (Fig. 2g). The results showed that malignant cells in metastatic LNs have stronger cell  
143 proliferative and invasive abilities.

#### 144 **Identification of a novel T cell type**

145 Reclustering of T cells identified 10 subclusters: CD4<sup>+</sup> Tregs, Cytotoxic CD8<sup>+</sup> T  
146 cells, Exhausted CD4<sup>+</sup> T cells, Follicular helper (T<sub>fh</sub>) T cells, Naïve CD4<sup>+</sup> T cells,  
147 Naïve T cells; NKT cells, Pre-exhausted CD8<sup>+</sup> T cells, Proliferating CD8<sup>+</sup> T cells, and  
148 Protective EGR1<sup>+</sup>CD4<sup>+</sup> T cells (Fig. 3a and 3b). In addition to the markers used above,  
149 we also found some other makers that can be used for cell population identification.  
150 For example, TYMS can be used for Pre-exhausted CD8<sup>+</sup> T cells identification, and  
151 RTKN2 can be used for Pre-exhausted CD4<sup>+</sup> Tregs identification (Fig. 3c,  
152 Supplementary Fig. 3). Notably, a novel cell type was identified, which was totally

153 different from preconceived cellular definitions. The novel cell type specifically  
154 highly expressed EGR1, and we named it as Protective EGR1<sup>+</sup>CD4<sup>+</sup>T cells. The  
155 mRNA expression level and protein level of EGR1 were significantly decreased in  
156 tumor tissues compared with normal tissues (Fig. 3d). Survival analysis showed that  
157 patients with high EGR1 levels had a better prognosis than those with low EGR1  
158 levels (Fig. 3e). Through cell frequency analysis, we found an interesting  
159 phenomenon that the proportion of CD4<sup>+</sup> Tregs tended to increase with PTC disease  
160 progression and Protective EGR1<sup>+</sup>CD4<sup>+</sup> T cells exhibited a quite opposite trend (Fig.  
161 3f). The results were validated with TCGA data calculated using Cibersortx (Fig. 3g)  
162 and further validated by the changes of marker gene expression levels in the TCGA  
163 THCA cohort (Supplementary Fig. 4a). These findings indicated that both of CD4<sup>+</sup>  
164 Tregs and Protective EGR1<sup>+</sup>CD4<sup>+</sup> T cells may have an important impact on disease  
165 progression, and our newly identified cell type (Protective EGR1<sup>+</sup>CD4<sup>+</sup>T cells) may  
166 be antagonistic to the CD4<sup>+</sup> Tregs.

167 We further characterized the functions of CD4<sup>+</sup> Tregs and Protective  
168 EGR1<sup>+</sup>CD4<sup>+</sup> T cells by comparing pathway activities. In the primary tumors, CD4<sup>+</sup>  
169 Tregs and Protective EGR1<sup>+</sup>CD4<sup>+</sup> T cells exhibited vastly different signaling  
170 pathways. CD4<sup>+</sup> Tregs were related to epithelial-mesenchymal transition (EMT) and  
171 hypoxia, whereas G2M checkpoint and KRAS signaling pathway were significantly  
172 down-regulated in Protective EGR1<sup>+</sup>CD4<sup>+</sup> T cells (Fig. 4a). In the metastatic LNs,  
173 mitotic spindle and oxidative phosphorylation were also down-regulated in Protective  
174 EGR1<sup>+</sup>CD4<sup>+</sup> T cells (Supplementary Fig. 4b). To screen for key genes related to  
175 tumorigenesis and tumor development in CD4<sup>+</sup> Tregs and Protective EGR1<sup>+</sup>CD4<sup>+</sup> T  
176 cells, we conducted SCENIC analysis and identified essential motifs in CD4<sup>+</sup> Tregs  
177 and Protective EGR1<sup>+</sup>CD4<sup>+</sup> T cells. FOSL2, ATF3, REL, and HES1 were CD4<sup>+</sup>  
178 Tregs-specific motifs. BCLAF1 and ETS1 motifs were highly activated in Protective  
179 EGR1<sup>+</sup>CD4<sup>+</sup> T cells (Fig. 4b). These results provided potential targets for inhibiting  
180 or reversing the formation of the immunosuppressive microenvironment.

181 The DEGs derived from Protective EGR1<sup>+</sup>CD4<sup>+</sup> T cells were identified,  
182 including 31 up-regulated mRNAs and 50 down-regulated mRNAs in primary tumors  
183 compared with paracancerous tissues (Supplementary Fig. 4c). The DEGs derived  
184 from CD4<sup>+</sup> Tregs were also identified (Supplementary Fig. 4d). Subsequently, we  
185 examined the immune checkpoints in the cell clusters (Fig. 4c and 4d). Notably, we  
186 found that TIGIT, an inhibitory checkpoint, was upregulated in Exhausted CD4<sup>+</sup> T

187 cells and CD96 was upregulated in Pre-exhausted CD8<sup>+</sup> T cells in metastatic LNs. In  
188 tumor tissues, PDCD1 (PD-1) and TIGIT were significantly upregulated in  
189 Exhausted CD4<sup>+</sup> T cells, and CD96 was significantly upregulated in Pre-exhausted  
190 CD8<sup>+</sup> T cells. Since TIGIT, CD96, and PDCD1 (PD-1) are markers of T cell  
191 exhaustion, these data indicated that Exhausted CD4<sup>+</sup> T cells and Pre-exhausted CD8<sup>+</sup>  
192 T cells were exhausted in the tumor microenvironment, which was consistent with our  
193 previous cell population classification results.

#### 194 **Neutrophils cells are extremely reduced in tumor**

195 For exploring the heterogeneity among myeloid cells, 1607 myeloid cells were  
196 clustered into 5 cell subtypes based on known markers described in previous studies:  
197 macrophages, dendritic cells, monocytes, neutrophils, and myeloid-derived suppressor  
198 cells (Fig. 5a and 5b). Through cell frequency analysis, a marked decrease of  
199 neutrophils was observed in tumors while the proportion of macrophages increased  
200 continuously as the disease progressed (Fig. 5c). The trend was consistent with TCGA  
201 data calculated by cibersortx (Fig. 5d). Survival analysis showed that disease-free  
202 survival (DFS) of patients with low-level dendritic cell was longer than that of the  
203 high-level group in the TCGA cohort (Fig. 5e). Similar results were observed in  
204 macrophages (Supplementary Fig. 5a). However, low-level neutrophil was observed  
205 to be associated with better prognosis (Supplementary Fig. 5b). These results  
206 suggested that macrophages, dendritic cells, and neutrophils are more relevant to the  
207 development of PTC.

208 We further characterized the functions of myeloid cell subtypes by comparing  
209 pathway activities. Compared with paracancerous tissues, the cancer hallmark-related  
210 pathways were relatively enriched in myeloid-derived suppressor cells from tumors,  
211 whereas they were generally down-regulated in neutrophils from tumors (Fig. 6a).  
212 These were consistent with the changes in cell proportions we observed earlier (Fig.  
213 5c). Compared with tumor tissues, however, some cancer hallmark-related pathways  
214 (i.e. mTORC1 signaling and E2F targets ) were down-regulated in myeloid-derived  
215 suppressor cells from metastatic LNs (Fig. 6b). The results indicated that  
216 myeloid-derived suppressor cells were involved in cancer cell proliferation, but not in  
217 tumor metastasis.

218 In order to screen for key genes related to tumor occurrence and development in  
219 myeloid cells, we conducted SCENIC analysis and identified essential motifs in  
220 myeloid cells subtypes. Similar to the results of pathway analysis, the overall

221 regulatory factors in neutrophils were also inconsistent with the other cell types (Fig.  
222 6c). We recognized that the decreased activity of a lot of motifs (i.e. YY1 and IRF5)  
223 and activation of the STAT3, ZNF143, and HCFC1 motifs led to the reduction of  
224 neutrophils.

225 As shown in Fig. 6d, cells from myeloid cell-derived cluster 8 uniquely  
226 expressed the M1 macrophages marker CCL5, whereas M2 macrophages markers  
227 including CTSB/CTSD/FN1 were relatively highly expressed in cluster 0. The  
228 proportion of cluster 0 was high in tumors and LNs, although the difference has not  
229 reached a significant level (Fig. 5c). All of this evidence certified that cluster 0  
230 represented an M2-like tumor-associated macrophages (TAM) cluster, the increase of  
231 which may be related to disease progression. Cluster 9 highly expressed the cytokines  
232 CCL17/CCL19/CCL22. These cytokines could bind to CCR4, a marker on the cell  
233 membrane of CD4<sup>+</sup> Tregs, and showed strong chemotaxis to CD4<sup>+</sup> Tregs<sup>37, 38</sup>. It  
234 corroborated with our above results that the increasing trend of CD4<sup>+</sup> Tregs with  
235 disease progression was coincident with that of myeloid cell-derived cluster 9 (Fig. 3f  
236 and 5c). The findings indicated that the dendritic cells (cluster 9) could recruit CD4<sup>+</sup>  
237 Tregs into the tumor regions, thereby acting as an immunosuppressive effect.

## 238 Discussion

239 At present, the study of molecular mechanisms underlying the occurrence and  
240 development of PTC mainly focused on the genetical alteration based on bulk  
241 sequencing data. We profiled integrated and heterologous transcriptional landscapes  
242 of PTC using single-cell sequencing methods, including cancer cells and TME of  
243 primary tumors and metastatic lesions. Through sequencing 28,205 cells, we found  
244 that the majority of cell clusters possessed strong heterogeneities. Tumor  
245 heterogeneity exists in various malignancies and remains not only between tumors but  
246 also within a single tumor<sup>39</sup>, which is considered as a cause of chemoresistance of  
247 cancer. In-depth knowledge of tumor heterogeneity of PTC will make molecular  
248 testing more reliable and accurate prior to surgery (whether to undergo the surgery or  
249 close follow-up only), and benefit to stratify the recurrence risk and personalized  
250 precision treatment (thyroidectomy or total thyroidectomy or plus radioiodine  
251 treatment). On the other hand, TME on disease progression and metastasis has also  
252 been confirmed in numerous diseases<sup>40, 41</sup>. Investigations of TME-related cellular and  
253 molecular events will provide a theoretical rationale for drug discovery and  
254 development, especially for targeted therapy and immunotherapy.



255 In addition to previously described cell types, we discovered a novel cell  
256 subpopulation, named Protective EGR1<sup>+</sup>CD4<sup>+</sup>T cells. EGR1 is a transcription factor  
257 primarily mediate cellular functions (i.e. cell growth, cancer progress and apoptosis)  
258 via the RAS/RAF/MEK/ERK signaling pathway<sup>42</sup>, which was a hallmark of PTC<sup>43</sup>.  
259 It has also been previously reported that p53 could bind to EGR1 promoter and  
260 subsequently resulted in efficient apoptosis<sup>44</sup>. EGR1 was usually considered a tumor  
261 suppressor in many human malignancies including PTC<sup>45, 46, 47, 48</sup>. By comparing the  
262 proportion of cells from different tissues and pathway enrichment analyzing, we  
263 found that KRAS signaling pathway (part of RAS/RAF/MEK/ERK signaling pathway)  
264 was significantly down-regulated in Protective EGR1<sup>+</sup>CD4<sup>+</sup> T cells. It indicated that  
265 Protective EGR1<sup>+</sup>CD4<sup>+</sup>T cells might inhibit the formation of the immunosuppressive  
266 microenvironment and tumor immune evasion via RAS/RAF/MEK/ERK signaling  
267 pathway, thereby restraining tumor growth. Therefore, EGR1 might represent a  
268 potential therapeutic target for PTC.

269 CD4<sup>+</sup> Tregs, were overall considered to disrupt anti-tumor immunity and then  
270 help tumor cells to achieve immune evasion, leading to the tumor growth and  
271 metastasis<sup>49</sup>. Our results also showed that CD4<sup>+</sup> Tregs had the greatest positive  
272 correlation with the process of EMT, which matched those reported in other studies of  
273 PTC patients<sup>50</sup>. Using pathway enrichment analysis, we found that relevant pathways  
274 associated with CD4<sup>+</sup> Tregs and Protective EGR1<sup>+</sup>CD4<sup>+</sup>T cells were almost the  
275 opposite. The proportion of CD4<sup>+</sup> Tregs among three samples increased in the disease  
276 progression order (paracancerous tissues < tumors < LNs) while the proportion of  
277 Protective EGR1<sup>+</sup>CD4<sup>+</sup>T cells decreased sequentially. This strongly suggested that  
278 CD4<sup>+</sup> Tregs and Protective EGR1<sup>+</sup>CD4<sup>+</sup>T cells might act antagonistically to each  
279 other.

280 Immunotherapy is an emerging method for cancer treatment and promising  
281 results have been obtained in both hematologic and solid tumors<sup>51, 52</sup>. T cell  
282 exhaustion is a critical mechanism of immune evasion. Blockade the PD1/PDL1  
283 interaction to reverse T cell exhaustion is considered a milestone achievement in the  
284 field of immunotherapy<sup>53, 54, 55</sup>. Our results showed that PDCD1 (PD-1), TIGIT, and  
285 CD96 could be suitable targets of immunotherapy in PTC patients without LN  
286 metastasis since they were upregulated in tumor tissues. However, the expression  
287 levels of TIGIT and CD96 were much higher than that of PDCD1 (PD-1) in  
288 LN-derived exhausted T cell types (Exhausted CD4<sup>+</sup> T cells and Pre-exhausted CD8<sup>+</sup>

289 T cells). Therefore, TIGIT and CD96 might be better therapeutic targets for  
290 immunotherapy in PTC patients with LN metastasis than PDCD1 (PD-1). Jill et al.<sup>56</sup>  
291 investigated the CD4<sup>+</sup> and CD8<sup>+</sup> T cell exhaustion in PTC patients with LN metastasis  
292 using flow cytometry, and found that CD8<sup>+</sup> T cell exhaustion was incomplete. This  
293 was most likely because TIGIT and CD96 were not included into analysis in their  
294 study, both of which were very important inhibitory immune checkpoints. However,  
295 their findings supported our conclusions to some extent that PDCD1 (PD-1) was not a  
296 suitable molecular target for the treatment of PTC with LN metastasis.

297 We initially applied a commonly used method inferCNV for the identification of  
298 malignant cells<sup>57</sup>, which was shown to be unable to identify efficiently malignant  
299 tumor cells from epithelial cells in this study. Thus, we adapted an integrative  
300 Bayesian segmentation approach called CopyKAT and solved the conundrum  
301 successfully<sup>35</sup>. As a result, more than half of tumor-derived epithelial cells were  
302 non-malignant cells, which might well explain the reason for the indolent clinical  
303 behavior of PTC. Additionally, there were also a very small number of malignant  
304 epithelial cells in paracancerous tissues, possibly due to the presence of the pre-tumor  
305 microenvironment in paracancerous tissues. There were several possible reasons. First,  
306 the pre-metastatic niche, a favorable microenvironment to tumor metastasis, formed in  
307 paracancerous tissues<sup>58</sup>, and in turn lead to intra-thyroid metastasis. The concept of  
308 intra-thyroid metastasis of thyroid cancer has not been described yet. The reason is  
309 possibly caused by the small size of the thyroid gland itself and the narrow lumen of  
310 artery/vein nourishing the thyroid gland. As is well-known, liver cancer tends to  
311 present with intrahepatic metastatic disease, mainly due to the large diameter of the  
312 portal vein and hepatic artery. Second, multifocal PTC has already existed within the  
313 thyroid gland, whereas the extremely tiny lesion cannot be detected under  
314 microscopic examination. Based on the two points above, thyroidectomy is  
315 necessary to be performed for patients with PTC at least to ensure a total removal of  
316 potential lesions. Third, CopyKAT is not able to discriminate malignant cells from  
317 non-malignant cells with hundred percent accuracy.

318 In summary, we initially investigated the single-cell level heterogeneity of  
319 primary PTC tumors and metastatic lesions. A novel cell type, named Protective  
320 EGR1+CD4+T cells, was identified, which might inhibit the formation of the  
321 immunosuppressive microenvironment and tumor immune evasion. TIGIT and CD96  
322 might be better therapeutic targets for immunotherapy in PTC patients with LN

323 metastasis than PDCD1 (PD-1). These findings would contribute to the further  
324 understanding of molecular mechanisms resulting in occurrence and development of  
325 PTC, and provide a theoretical rationale for targeted therapy and immunotherapy.

326

327 **Methods**

328 **Sample collection and clinical information**

329 Seven patients diagnosed with PTC were obtained from Shanghai Tenth People's  
330 Hospital. A total of 15 tissue samples (7 tumor tissues, 6 paracancerous tissues, and 2  
331 metastatic LNs) were obtained from 7 PTC patients. Written informed consent was  
332 obtained from all patients in the present study. Histological diagnosis of all the  
333 samples was confirmed by the pathology department.

334 **Tissue digestion and single-cell suspension preparation**

335 Cells of each sample were firstly stained with two fluorescent dye, Calcein AM  
336 (Thermo Fisher Scientific Cat. No. C1430) and Draq7 (Cat. No. 564904), for  
337 precisely determination of cell concentration and viability via BD Rhapsody™  
338 Scanner before single-cell multiplexing labeling. The cells of each sample were  
339 sequentially labeled with BD Human Single-Cell Multiplexing Kit (Cat. No. 633781)  
340 which utilizing an innovative antibody-oligo technology<sup>22</sup> mainly to provide higher  
341 sample throughput and eliminate batch effect for single-cell library preparation and  
342 sequencing. A set of 12 antibodies in this kit recognize the same universally expressed  
343 cell-surface antigen of human cells. Each antibody is conjugated with a Sample Tag, a  
344 unique 45-nucleotide barcode sequence. Briefly, cells from each sample were labeled  
345 by antibodies with different sample tags respectively and washed twice with BD  
346 Pharmingen™ Stain Buffer (FBS) (Cat. No. 554656) before pooling all samples  
347 together. BD Rhapsody Express system<sup>23</sup> based on Fan et al. was utilized for  
348 single-cell transcriptome capture. Pooled samples were then loaded in one BD  
349 Rhapsody™ Cartridge that was primed and treated strictly following the  
350 manufacturer's protocol (BD Biosciences). Cell Capture Beads (BD Biosciences)  
351 were then loaded excessively onto the cartridge to ensure that nearly every micro-well  
352 contains one bead, and excess beads were washed away from the cartridge. Viable  
353 cells with beads captured in wells were detected in BD Rhapsody™. Then cells were  
354 lysed, Cell Capture Beads were retrieved and washed before performing reverse  
355 transcription and treatment with exonuclease I.

356 **Library construction and sequencing**

357 Transcriptome and SampleTag information of single-cells was obtained through BD  
358 Rhapsody System. Microbeads-captured single cell transcriptome and SampleTag  
359 sequences were generated into the cDNA library and SampleTag library separately

360 containing cell labels and unique molecular identifiers (UMI) information. Briefly,  
361 double-strand cDNA was firstly generated from microbeads-captured single-cell  
362 transcriptome through several steps including reverse transcription, second-strand  
363 synthesis, end preparation, adapter ligation, and whole transcriptome amplification.  
364 Then final cDNA library was generated from double-strand full-length cDNA by  
365 random priming amplification with BD Rhapsody cDNA Kit (BD Biosciences,  
366 Catalog No.: 633773) and BD Rhapsody Targeted mRNA & AbSeq Amplification Kit  
367 (BD Biosciences, Catalog No.: 633774). On the other hand, the SampleTag library  
368 was generated from microbeads-captured single-cell SampleTag sequences through  
369 several steps including reverse transcription, nest PCR, and final index PCR. Libraries  
370 were sequenced on the NovaSeq platform (Illumina).

### 371 **Raw data preprocessing and quality control**

372 Raw sequencing reads of the cDNA library and SampleTag library were processed  
373 through the BD Rhapsody Whole Transcriptome Assay Analysis Pipeline (Early  
374 access), which included filtering by reads quality, annotating reads, annotating  
375 molecules, determining putative cells, and generating single-cell expression matrix.  
376 Briefly, read pairs with low sequencing quality were firstly removed. The  
377 quality-filtered R1 reads were analyzed to identify the sequence of cell labels, UMI  
378 sequence, and poly-dT tail sequence, meanwhile the quality-filtered R2 reads were  
379 mapped to Genome Reference Consortium Human Build 38 (GRCh38) using STAR  
380 (version 2.5.2b) in the reads annotation step. Further adjustment was performed with  
381 the recursive substitution error correction (RSEC) and distribution-based error  
382 correction (DBEC) algorithms to remove artifact molecules due to amplification bias  
383 in the molecules annotation step. Putative cells were distinguished from background  
384 noise with second derivative analysis in the putative cell determination step. Finally,  
385 putative cells information was combined with molecules adjusted by the recursive  
386 substitution error correction and distribution-based error correction algorithms to  
387 generate a single-cell expression matrix. The pipeline also determined the sample  
388 origin of every single cells via the sample determination algorithm according to the  
389 sequencing reads of the SampleTag library. The algorithm classified all putative single  
390 cell into three categories: Multiplet, two or more SampleTag exceed their minimum  
391 thresholds, indicating more than one actual cell in one micro-well. Undetermined, not  
392 enough SampleTag reads for the sample origin. SampleTag01-12, only one  
393 SampleTag exceed their minimum thresholds. . Among all the output files, Matrix for

394 UMI counts per cell corrected by DBEC and SampleTag annotation result were used  
395 for downstream clustering analysis.

#### 396 **Dimension reduction and clustering**

397 The R package Seurat<sup>23</sup> was utilized for subsequent analysis. Raw gene expression  
398 matrices from the cartridge were read into R (version 3.6.0) and converted to Seurat  
399 objects. Cells label as “Undetermined” and “Multiple” were excluded in the following  
400 analysis. The gene expression matrix was then normalized to the total cellular UMI  
401 count. Top 2000 features were selected as highly variable genes for further clustering  
402 analysis. In order to reduce dimensionality, PCA was performed based on the highly  
403 variable genes after scaling the data with respect to UMI counts. On top of that, the  
404 first 9 principal components were chosen for downstream clustering based on the  
405 heatmap of principle components, and the elbow plot of principle components to  
406 further reduce dimensionality using the UMAP algorithm. The transcriptional markers  
407 of each cluster were calculated using the FindAllMarkers function with theMAST  
408 package to run the DE testing under the following criteria: log<sub>2</sub> fold change > 0.1; p <  
409 0.05; min. percentage > 0.25. Top 500 markers of each cluster were then selected to  
410 perform a heatmap plot.

#### 411 **Cell annotation and cell type identification**

412 Cell populations were matched to cell types based on the expression of known marker  
413 genes and previously identified expression signatures<sup>23, 24, 25, 26, 27, 28</sup>.

#### 414 **Comparison of cell clusters and cell type proportion**

415 The change in the fraction of the different cell types was separately computed for each  
416 sample across all clusters, as the fraction of cell in each cluster, out of the total  
417 number of cells<sup>29</sup>. To assess a statistically significant difference in a fraction of a  
418 specific cell type, we performed paired t-test.

#### 419 **Significantly dysregulated genes identification**

420 We identified differentially expressed genes (DEGs) based on analysis of the MAST  
421 package using the R. The threshold of DEGs was set as: 1)P-value of F test < 0.05; 2)  
422 |FC| ≥ 1.5.

#### 423 **External data validation with TCGA datasets**

424 CIBERSORTx was used to detect the abundance of cell types identified in the present  
425 work in bulk RNA-seq data<sup>30</sup>. After calculated the relative abundance of each cell  
426 type, we divided the patients into two groups: high 50% and low 50%. Subsequently,  
427 Kaplan-Meier analysis was performed using ggsurvplot function of the R package

428 ‘survminer’. Whether the occurrence of cell types in the different subgroups showed  
429 significant differences was evaluated by Wilcoxon test.

#### 430 **Functional annotation and enrichment**

431 GO enrichment and KEGG enrichment of DEGs were performed using Fisher exact  
432 test with Benjamini-Hochberg multiple testing adjustment. The results were  
433 visualized using R package. Gene set variation analysis (GSVA)<sup>31</sup> was performed  
434 using 50 hallmark-related gene sets, as described in the GSVA package.

#### 435 **Identification of hub regulons with SENIC**

436 In order to investigate the gene regulatory network of different sample groups, we  
437 utilized SCENIC<sup>32</sup> using the R.

#### 438 **Cell-cell communication analysis based on ligand-receptor pairs**

439 Cell-cell communication at the molecular level was analyzed with CellPhoneDB<sup>33</sup>.

#### 440 **Cell trajectory analysis with Monocle**

441 In order to reveal the development of malignant cells, we employed Monocle 2, an R  
442 package designed for single cell trajectories<sup>34</sup>. After obtaining the differentially  
443 expressed genes through differential Gene Test function, the trajectories were  
444 visualized as 2D tSNE plots.

#### 445 **Drug-target analysis with TCMID database**

446 After obtaining the differentially expressed genes, we obtain the targeted relationship  
447 between drugs and genes from the TCMID database  
448 (<http://www.megabionet.org/tcmid>).

#### 449 **CNV Estimation**

450 CopyKAT<sup>35</sup> (Copynumber Karyotyping of Tumors), a R package was performed to  
451 separate tumor cells from normal cells using high-throughput sc-RNAseq data. Cells  
452 with extensive genome-wide copy number aberrations (aneuploidy) are considered as  
453 tumor cells, whereas stromal normal cells and immune cells often have 2N diploid or  
454 near-diploid copy number profiles.

#### 455 **Statistical analysis**

456 Box plots were drawn with the R base package. Hence, the boxes span from the 25th  
457 to the 75th percentiles. Violin plots were generated by the ggplot2 R package.  
458 Unpaired two-tailed t-tests was used to compare the difference between two groups.  
459 While One-way analysis of variance (ANOVA) was used for multiple group  
460 comparisons.

#### 461 **Data availability**

462 The cancer genome atlas (TCGA) thyroid cancer (THCA) cohort were downloaded  
463 from UCSC XENA (<http://xena.ucsc.edu/>).

464

465 **References**

466 1. Sung H, *et al.* Global cancer statistics 2020: GLOBOCAN estimates of incidence and  
467 mortality worldwide for 36 cancers in 185 countries. (2021).

468

469 2. Fagin JA, Wells SA, Jr. Biologic and Clinical Perspectives on Thyroid Cancer. *N Engl J*  
470 *Med* **375**, 1054-1067 (2016).

471

472 3. Yu J, *et al.* Lymph node metastasis prediction of papillary thyroid carcinoma based on  
473 transfer learning radiomics. *Nat Commun* **11**, 4807 (2020).

474

475 4. Cohen EE, *et al.* Axitinib is an active treatment for all histologic subtypes of advanced  
476 thyroid cancer: results from a phase II study. *J Clin Oncol* **26**, 4708-4713 (2008).

477

478 5. Jiao C, *et al.* REGgamma ablation impedes dedifferentiation of anaplastic thyroid  
479 carcinoma and accentuates radio-therapeutic response by regulating the  
480 Smad7-TGF-beta pathway. *Cell Death Differ* **27**, 497-508 (2020).

481

482 6. Laetitia G, Sven S, Fabrice J. Combinatorial Therapies in Thyroid Cancer: An  
483 Overview of Preclinical and Clinical Progresses. *Cells* **9**, (2020).

484

485 7. Hong CM, Ahn BC. Redifferentiation of Radioiodine Refractory Differentiated Thyroid



- 486 Cancer for Reapplication of I-131 Therapy. *Front Endocrinol (Lausanne)* **8**, 260  
487 (2017).  
488
- 489 8. Shen X, *et al.* Patient Age-Associated Mortality Risk Is Differentiated by BRAF V600E  
490 Status in Papillary Thyroid Cancer. **36**, 438-445 (2018).  
491
- 492 9. Pozdeyev N, *et al.* Genetic Analysis of 779 Advanced Differentiated and Anaplastic  
493 Thyroid Cancers. **24**, 3059-3068 (2018).  
494
- 495 10. Liu R, Bishop J, Zhu G, Zhang T, Ladenson P, Xing MJJo. Mortality Risk Stratification  
496 by Combining BRAF V600E and TERT Promoter Mutations in Papillary Thyroid  
497 Cancer: Genetic Duet of BRAF and TERT Promoter Mutations in Thyroid Cancer  
498 Mortality. **3**, 202-208 (2017).  
499
- 500 11. Li Y, *et al.* CYP2S1 is a synthetic lethal target in BRAF-driven thyroid cancers. **5**, 191  
501 (2020).  
502
- 503 12. Tekpli X, *et al.* An independent poor-prognosis subtype of breast cancer defined by a  
504 distinct tumor immune microenvironment. *Nat Commun* **10**, 5499 (2019).  
505
- 506 13. Roehlecke C, Schmidt MHH. Tunneling Nanotubes and Tumor Microtubes in Cancer.  
507 *Cancers (Basel)* **12**, (2020).

508

509 14. Oczko-Wojciechowska M, *et al.* Impact of the Tumor Microenvironment on the Gene  
510 Expression Profile in Papillary Thyroid Cancer. *Pathobiology* **87**, 143-154 (2020).

511

512 15. Jolly LA, *et al.* Fibroblast-Mediated Collagen Remodeling Within the Tumor  
513 Microenvironment Facilitates Progression of Thyroid Cancers Driven by BrafV600E  
514 and Pten Loss. *Cancer Res* **76**, 1804-1813 (2016).

515

516 16. Robertson A, *et al.* Identification of Differential Tumor Subtypes of T1 Bladder Cancer.  
517 **78**, 533-537 (2020).

518

519 17. Mer A, *et al.* Biological and therapeutic implications of a unique subtype of NPM1  
520 mutated AML. **12**, 1054 (2021).

521

522 18. Job S, *et al.* Identification of Four Immune Subtypes Characterized by Distinct  
523 Composition and Functions of Tumor Microenvironment in Intrahepatic  
524 Cholangiocarcinoma. **72**, 965-981 (2020).

525

526 19. Wright G, *et al.* A Probabilistic Classification Tool for Genetic Subtypes of Diffuse  
527 Large B Cell Lymphoma with Therapeutic Implications. **37**, 551-568.e514 (2020).

528

529 20. Guruprasad P, Lee Y, Kim K, Ruella MJTJoem. The current landscape of single-cell

530 transcriptomics for cancer immunotherapy. **218**, (2021).

531

532 21. Lin W, *et al.* Single-cell transcriptome analysis of tumor and stromal compartments of  
533 pancreatic ductal adenocarcinoma primary tumors and metastatic lesions. *Genome*  
534 *Med* **12**, 80 (2020).

535

536 22. Stoeckius M, *et al.* Simultaneous epitope and transcriptome measurement in single  
537 cells. **14**, 865-868 (2017).

538

539 23. Butler A, Hoffman P, Smibert P, Papalexi E, Satija RJNb. Integrating single-cell  
540 transcriptomic data across different conditions, technologies, and species. **36**,  
541 411-420 (2018).

542

543 24. Jerby-Amon L, *et al.* A Cancer Cell Program Promotes T Cell Exclusion and  
544 Resistance to Checkpoint Blockade. **175**, 984-997.e924 (2018).

545

546 25. Peng J, *et al.* Single-cell RNA-seq highlights intra-tumoral heterogeneity and  
547 malignant progression in pancreatic ductal adenocarcinoma. **29**, 725-738 (2019).

548

549 26. Zhang X, *et al.* CellMarker: a manually curated resource of cell markers in human and  
550 mouse. **47**, D721-D728 (2019).

551

- 552 27. Zilionis R, *et al.* Single-Cell Transcriptomics of Human and Mouse Lung Cancers  
553 Reveals Conserved Myeloid Populations across Individuals and Species. **50**,  
554 1317-1334.e1310 (2019).  
555
- 556 28. Luoma A, *et al.* Molecular Pathways of Colon Inflammation Induced by Cancer  
557 Immunotherapy. **182**, 655-671.e622 (2020).  
558
- 559 29. Habib N, *et al.* Disease-associated astrocytes in Alzheimer's disease and aging. *Nat*  
560 *Neurosci* **23**, 701-706 (2020).  
561
- 562 30. Steen CB, Liu CL, Alizadeh AA, Newman AM. Profiling Cell Type Abundance and  
563 Expression in Bulk Tissues with CIBERSORTx. *Methods Mol Biol* **2117**, 135-157  
564 (2020).  
565
- 566 31. Hänzelmann S, Castelo R, Guinney JJBb. GSVA: gene set variation analysis for  
567 microarray and RNA-seq data. **14**, 7 (2013).  
568
- 569 32. Aibar S, *et al.* SCENIC: single-cell regulatory network inference and clustering. **14**,  
570 1083-1086 (2017).  
571
- 572 33. Efremova M, Vento-Tormo M, Teichmann S, Vento-Tormo RJNp. CellPhoneDB:  
573 inferring cell-cell communication from combined expression of multi-subunit

574 ligand-receptor complexes. **15**, 1484-1506 (2020).

575

576 34. Trapnell C, *et al.* The dynamics and regulators of cell fate decisions are revealed by  
577 pseudotemporal ordering of single cells. *Nat Biotechnol* **32**, 381-386 (2014).

578

579 35. Gao R, *et al.* Delineating copy number and clonal substructure in human tumors from  
580 single-cell transcriptomes. *Nat Biotechnol*, (2021).

581

582 36. Wolford C, *et al.* Transcription factor ATF3 links host adaptive response to breast  
583 cancer metastasis. **123**, 2893-2906 (2013).

584

585 37. Pere H, *et al.* A CCR4 antagonist combined with vaccines induces antigen-specific  
586 CD8+ T cells and tumor immunity against self antigens. **118**, 4853-4862 (2011).

587

588 38. Berlato C, *et al.* A CCR4 antagonist reverses the tumor-promoting microenvironment  
589 of renal cancer. **127**, 801-813 (2017).

590

591 39. Vinci M, *et al.* Functional diversity and cooperativity between subclonal populations of  
592 pediatric glioblastoma and diffuse intrinsic pontine glioma cells. *Nat Med* **24**,  
593 1204-1215 (2018).

594

595 40. Rubio-Perez C, *et al.* Immune cell profiling of the cerebrospinal fluid enables the

- 596 characterization of the brain metastasis microenvironment. **12**, 1503 (2021).
- 597
- 598 41. Chen YP, *et al.* Single-cell transcriptomics reveals regulators underlying immune cell  
599 diversity and immune subtypes associated with prognosis in nasopharyngeal  
600 carcinoma. *Cell Res* **30**, 1024-1042 (2020).
- 601
- 602 42. Cook PJ, *et al.* Cox-2-derived PGE2 induces Id1-dependent radiation resistance and  
603 self-renewal in experimental glioblastoma. *Neuro Oncol* **18**, 1379-1389 (2016).
- 604
- 605 43. Jin S, Borkhuu O, Bao W, Yang YT. Signaling Pathways in Thyroid Cancer and Their  
606 Therapeutic Implications. *J Clin Med Res* **8**, 284-296 (2016).
- 607
- 608 44. Yu J, Baron V, Mercola D, Mustelin T, Adamson ED. A network of p73, p53 and Egr1  
609 is required for efficient apoptosis in tumor cells. *Cell Death Differ* **14**, 436-446 (2007).
- 610
- 611 45. Jung SN, *et al.* EGR1/GADD45alpha Activation by ROS of Non-Thermal Plasma  
612 Mediates Cell Death in Thyroid Carcinoma. *Cancers (Basel)* **13**, (2021).
- 613
- 614 46. Crawford NT, McIntyre AJ, McCormick A, D'Costa ZC, Buckley NE, Mullan PB. TBX2  
615 interacts with heterochromatin protein 1 to recruit a novel repression complex to  
616 EGR1-targeted promoters to drive the proliferation of breast cancer cells. *Oncogene*  
617 **38**, 5971-5986 (2019).

618

619 47. Ryu JW, *et al.* Paradoxical induction of growth arrest and apoptosis by EGF via the  
620 up-regulation of PTEN by activating Redox factor-1/Egr-1 in human lung cancer cells.  
621 *Oncotarget* **8**, 4181-4195 (2017).

622

623 48. Peng WX, *et al.* Egr-1 regulates irradiation-induced autophagy through Atg4B to  
624 promote radioresistance in hepatocellular carcinoma cells. *Oncogenesis* **6**, e292  
625 (2017).

626

627 49. Gonzalez-Navajas JM, *et al.* The Impact of Tregs on the Anticancer Immunity and the  
628 Efficacy of Immune Checkpoint Inhibitor Therapies. *Front Immunol* **12**, 625783 (2021).

629

630 50. Antonelli A, Ferrari SM, Fallahi P. Current and future immunotherapies for thyroid  
631 cancer. *Expert Rev Anticancer Ther* **18**, 149-159 (2018).

632

633 51. Lv M, *et al.* Manganese is critical for antitumor immune responses via cGAS-STING  
634 and improves the efficacy of clinical immunotherapy. *Cell Res* **30**, 966-979 (2020).

635

636 52. Marigo I, *et al.* T Cell Cancer Therapy Requires CD40-CD40L Activation of Tumor  
637 Necrosis Factor and Inducible Nitric-Oxide-Synthase-Producing Dendritic Cells.  
638 *Cancer Cell* **30**, 377-390 (2016).

639

- 640 53. Cortez MA, *et al.* Bone morphogenetic protein 7 promotes resistance to  
641 immunotherapy. *Nat Commun* **11**, 4840 (2020).  
642
- 643 54. Huang Z, *et al.* IL-27 promotes the expansion of self-renewing CD8(+) T cells in  
644 persistent viral infection. *J Exp Med* **216**, 1791-1808 (2019).  
645
- 646 55. Lei Q, Wang D, Sun K, Wang L, Zhang Y. Resistance Mechanisms of Anti-PD1/PDL1  
647 Therapy in Solid Tumors. *Front Cell Dev Biol* **8**, 672 (2020).  
648
- 649 56. Severson JJ, *et al.* PD-1+Tim-3+ CD8+ T Lymphocytes Display Varied Degrees of  
650 Functional Exhaustion in Patients with Regionally Metastatic Differentiated Thyroid  
651 Cancer. *Cancer Immunol Res* **3**, 620-630 (2015).  
652
- 653 57. Tirosh I, *et al.* Dissecting the multicellular ecosystem of metastatic melanoma by  
654 single-cell RNA-seq. **352**, 189-196 (2016).  
655
- 656 58. Liu Y, Cao X. Characteristics and Significance of the Pre-metastatic Niche. *Cancer*  
657 *Cell* **30**, 668-681 (2016).  
658  
659



660 **Acknowledgments**

661 This work was supported by Shanghai Municipal Commission of Health and Family  
662 Planning Commission (2019SY062).

663 **Authors' contributions**

664 BH J, ZS W, ZQ Y, and Y R conceived and designed the study. WL J, CG T, and ZS  
665 W contributed to carry out the experiments. BH J, CG H, and C Y contributed to data  
666 analysis. ZS W, BH J, and ZQ Y wrote the manuscript. YR, WL J, and ZQ Y revised  
667 the paper. All authors read and approved the final manuscript.

668 **Competing Interests**

669 The authors have declared that no competing interest exists.

670

671 **Figure legends**

672 **Fig.1 Overall design and single cell atlas in papillary thyroid carcinoma. a**

673 Workflow diagram showing the processing of samples. **b** UMAP plots of total cells,  
674 colored by the sample origin (tumor, metastatic LN, and paracancerous tissues). **c**  
675 Expression of cell marker genes. **d** Changes in frequency of multiple cell types and  
676 clusters in tumors and metastatic LNs. Asterisks on the left of the vertical line denote  
677 statistically significant differences between tumors and paracancerous tissues while  
678 asterisks on the right are used to show statistically significant differences between  
679 metastatic LNs and tumors. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ , two-tailed t-tests. **e**  
680 Interaction network constructed by CellPhoneDB. Size of circles and color of arrows  
681 represent interaction counts, and brighter color and larger size mean more interaction  
682 with other cell types.

683 **Fig.2 Identification of malignant cells in epithelial cells. a** Clonal substructure of

684 epithelial cells delineated by clustering single-cell copy number profiles inferred from  
685 scRNA-seq data by CopyKAT. **b** UMAP plots of total epithelial cells, colored by the  
686 sample origin (left and middle). Cell counts of malignant and non-malignant cells,  
687 colored by the sample origin (right). **c** Differentiation trajectory of epithelial cells,  
688 with each color coded for pseudotime (right) and clusters (left). **d** Heatmap of the area  
689 under the curve (AUC) scores of transcription factor (TF) motifs estimated by  
690 SCENIC. Shown are differentially activated motifs in malignant and non-malignant  
691 cells, respectively. **e** High level of CREM and ETS1 predicted good prognosis in the  
692 TCGA THCA cohort. Log-rank  $p$  value  $< 0.05$  was considered as statistically  
693 significant. **f** BHLHE40 was highly expressed in LN samples ( $p < 0.001$ ). **g** GO  
694 enrichment analysis of up-regulated genes in malignant lymphatic metastasis cells.

695 **Fig.3 Heterogeneity of T cell populations. a** UMAP plot of T cells color-coded by

696 their associated cell types. **b** Dotplot of cell markers; sizes of dots represent  
697 abundance while color represents expression level. **c** Potential new cell markers. **d**  
698 The protein level of EGR1 was decreased in tumor tissues compared with normal  
699 tissues. **e** High level of EGR1 predicted good prognosis in the TCGA THCA cohort.  
700 **f** Changes in frequency of multiple cell types in T cell populations. Asterisks on the  
701 left of the vertical line denote statistically significant differences between tumors and  
702 paracancerous tissues while asterisks on the right are used to show statistically  
703 significant differences between LNs and tumors. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ ,  
704 two-tailed t-tests. **g** Violin of cell abundance predicted from the TCGA THCA cohort

705 by CIBERSORTx.

706 **Fig.4 Novel cell type, named Protective EGR1<sup>+</sup>CD4<sup>+</sup> T cells, and potential**  
707 **therapeutic targets. a** Differences in 50 hallmark pathway activities scored with  
708 GSVA software. Shown are t values calculated by a linear model. **b** Heatmap of the  
709 AUC scores of TF motifs estimated by SCENIC. Shown are differentially activated  
710 motifs in CD4<sup>+</sup> Tregs and Protective EGR1<sup>+</sup>CD4<sup>+</sup> T cells, respectively. **c-d** Heatmap  
711 of positive and negative immune checkpoint expression on T cells in LNs (**c**) and  
712 tumors (**d**), respectively.

713 **Fig.5 Heterogeneity of Myeloid cell populations. a** UMAP plot of Myeloid cells  
714 color-coded by their associated cell types. **b** Dotplot of cell markers; sizes of dots  
715 represent abundance while color represents expression level. **c** Changes in frequency  
716 of multiple cell types and clusters in Myeloid cell populations. Asterisks on the left of  
717 the vertical line denote statistically significant differences between tumors and  
718 paraneoplastic tissues while asterisks on the right are used to show statistically  
719 significant differences between LNs and tumors. \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001,  
720 two-tailed t-tests. **d** Violin of Macrophage abundance predicted from the TCGA  
721 THCA cohort by CIBERSORTx. **e** Kaplan-Meier curves of DFS based on the  
722 percentage of dendritic cells in the TCGA database.

723 **Fig.6 M2 macrophages were strongly enriched in the tumor tissues. a-b** Heatmap  
724 shows the differences in pathway activities scored by GSVA between different sample  
725 origins. Shown are t values calculated by a linear model. **c** Heatmap of the AUC  
726 scores of TF motifs estimated by SCENIC. Shown are differentially activated motifs  
727 in subtypes of Myeloid cells, respectively. **d** Violin plot shows the expression level of  
728 related genes in Macrophage subclusters (left) and cytokines in dendritic cells (right).

### 729 **Supplementary information**

730 **Supplementary Fig. 1 Identification of major cell types in PTC.** UMAP plots for  
731 expression of the marker genes from **Fig 1c** and of additional marker genes for major  
732 cell types. For B cells: CD19, MS4A1(CD20), CD38, CD79A, and CD79B; for CD4<sup>+</sup>  
733 T cells: CD4 and CD3D; for CD8<sup>+</sup>T cells: CD8A and CD3D; for Endothelial cells:  
734 CD34 and CD31(PECAM); for Epithelial cells: EPCAM and KRT18; for Fibroblasts:  
735 COL1A1; for Myeloid cells: CD14, CD86, ITGAX, CD80, CD83, and ITGAM; for  
736 Naive T cells: CCR7 and CD3D; for NKT cells: NKG7 and CD3D; for Plasma cells:






737 CD79A and SDC1.

738 **Supplementary Fig. 2 Overview of the 28,205 single cells from tumors,**  
739 **paracancerous tissues, and metastatic LNs. a** The fraction of multiple cell types  
740 originating from 7 tumor tissues, 6 paracancerous tissues, and 2 metastatic LNs. **b** The  
741 fraction of multiple cell types originating from 15 samples. **c** The number of multiple  
742 cell types. **d** Box plots of the number of transcripts.


743 **Supplementary Fig. 3 Potential new cell markers in T cells.**

744 **Supplementary Fig. 4 DEGs related to CD4<sup>+</sup>Tregs and transitional EGR1<sup>+</sup>CD4<sup>+</sup>T**  
745 **cells. a** The expression of the maker genes in the TCGA THCA cohort. **b** Differences  
746 in 50 hallmark pathway activities scored with GSEA software. Shown are t values  
747 calculated by a linear model. **c** DEGs related to Protective EGR1<sup>+</sup>CD4<sup>+</sup> T cells in  
748 tumors and LNs, respectively. **d** DEGs related to CD4<sup>+</sup>Tregs in tumors and LNs,  
749 respectively. Upregulated genes and downregulated genes were colored in red and  
750 blue, respectively.  $FC \geq 2$ .

751 **Supplementary Fig. 5 External verification based on the TCGA data. a** High level  
752 of Macrophage abundance predicted poor prognosis in the TCGA THCA cohort, and  
753 neutrophil was the opposite. **b** Kaplan-Meier survival curve for IFITM2.







**a****b****c****d****e**



**a**

medRxiv preprint doi: <https://doi.org/10.1101/2021.02.24.21251881>; this version posted April 8, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

CD4+Tregs Naive T cells  
Follicular helper (Tfh) T cells Proliferating CD8+T cells Proliferating CD4+T cells  
Naive CD4+T cells Protective EGR1+CD4+T cells

**b****c****RTKN2****d****e****f****g**